title: Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
abstract: A woman diagnosed of a renal cell carcinoma in 1989 had a metastatic kidney cancer localised in subcutaneous nodules, gut and lung in 2007. Sorafenib treatment was initiated a 400 mg orally twice a day. The patient developed generalised erythematous skin eruptions and two weeks later a widespread erythematous maculopapular eruption located exclusively on the legs and arms, along with an objective response. The most likely cause of the generalised erythematous skin eruptions was considered to be sorafenib because of the close temporal relationship between exposure to the drug and onset of symptoms. Furthermore, a relationship between sorafenib skin toxicity and treatment efficacy was observed. This therapeutic efficacy of EGFR inhibitors and cutaneous side effects should be better assessed in large cohorts or trials to determine whether the skin toxicity of patients can be linked to an objective antitumour response.
authors.affiliation: Oncology Service, Hospital de Sagunto, Universidad de Valencia, Valencia, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Galán Brotons
authors.forename: Joaquín
authors.initials: J
authors.lastname: Borrás-Blasco
authors.forename: J Dolores
authors.initials: JD
authors.lastname: Rosique-Robles
authors.forename: José María
authors.initials: JM
authors.lastname: Vicent Verge
authors.forename: Md Elvira
authors.initials: ME
authors.lastname: Casterá
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D003873:Dermatitis, Exfoliative / Q000139:chemically induced* / Q000175:diagnosis; D003875:Drug Eruptions / Q000175:diagnosis; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use*; D012867:Skin / Q000187:drug effects; D000077157:Sorafenib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib